GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES THE EUROPEAN COMMISSION''S APPROVAL OF CARVYKTI FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
GENSCRIPT BIO: FORM OF PROXY FOR 2024 ANNUAL GENERAL MEETING
GENSCRIPT BIO: PROPOSALS FOR (1) GRANTING OF GENERAL MANDATES TO ISSUE NEW SHARES AND TO REPURCHASE SHARES, (2) RE-ELECTION OF RETIRING DIRECTORS, (3) AMENDMENT OF THE SHARE OPTION SCHEME, (4) AMENDMENT OF THE 2019 RESTRICTED SHARE AWARD SCHEME, (5) AMENDMENT OF THE 2021
GENSCRIPT BIO: NOTICE OF ANNUAL GENERAL MEETING
GENSCRIPT BIO: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023
GENSCRIPT BIO: ANNUAL REPORT 2023
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 31 MARCH 2024
GENSCRIPT BIO: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES AND ADOPTION OF THE AMENDED MEMORANDUM AND ARTICLES
GENSCRIPT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
GENSCRIPT BIO: APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGE IN COMPOSITION OF BOARD COMMITTEE
GENSCRIPT BIO: Nomination Committee -Terms of Reference
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH ANNOUNCES THE U.S. FDA''S APPROVAL OF CARVYKTI FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
GENSCRIPT BIO: Next Day Disclosure Return
GENSCRIPT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH USA INC. ENTERS INTO MASTER MANUFACTURING AND SUPPLY SERVICES AGREEMENT WITH NOVARTIS PHARMACEUTICALS CORPORATION
GENSCRIPT BIO: Next Day Disclosure Return
GENSCRIPT BIO: VOLUNTARY ANNOUNCEMENT: LEGEND BIOTECH ANNOUNCES PUBLICATION OF INAUGURAL ESG REPORT
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES POSITIVE OPINION FROM THE U.S. FDA ODAC FOR CARVYKTI FOR THE EARLIER TREATMENT OF PATIENT WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
GENSCRIPT BIO: GRANT OF RESTRICTED SHARES
No Data